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Introduction 
 
The usage of soy isolate protein formula for infants 
was recommended by Indonesian Pediatrics 
Association (IDAI) through the recommendation of 
Cow’s Milk Protein Allergy (CMPA) management 
in 2014. Soy Infant Formula (SIF) has been being 
used for Infants with Cow’s Milk Protein Allergy 
(CMPA) as well as for several other related medical 
indications such as post diarrhea lactose intolerance, 
galactosemia and primary lactase deficiency.1 At 
early stage of soy formula, it had several 
deficiencies, infant acceptability, growth, and 
incomparable with milk-base formula. Current SIF 
is made from soy protein isolate that contain 2.2– 2.6 
g of protein per 100 calories, it is higher than milk-
based formula and both showed same growth and 
development in infants.2 It contains different fibers, 
phytate, digestibility, protease inhibitor and 
proteins. SIF is easily digestible and contain high 
amino acid content fortified with L-methionine, L-
carnitine and taurine. High content of phytate is 
overcome with zinc and iron fortification as well as 
increased levels of calcium and phosphor.3 
American Academy of Pediatrics recommends 
isolated soy protein-based formulas as a safe and 
effective alternative for providing appropriate 
nutrition for normal growth and development for 
term infants whose nutritional needs are not being 
met from maternal breast milk or cow’s milk-based 
formulas.3,4 
Soy isolate protein formula is commonly 
used as management of CMPA besides extensively 
hydrolyzed formula (eHF) and amino acid formula 
(AAF). Each formula possesses its own indications, 
advantages and disadvantages. The AAP (American 
Academy of Pediatrics) and the ESPGHAN 
(European Society for Pediatrics Gastroenterology 
Hepatology and Nutrition) recommended that SIF is 
a rational option and can be justified in CMPA 
children.3,4 Based on the Indonesia Pediatrics 
Association (IDAI) guidelines, the choice of 
formula for CMPA is restricted between eHF, AAF 
or SIF. According to the guideline, SIF is an 
alternative formula for infant with low to moderate 
allergy symptoms when there is an issue with 
affordability or availability of eHF.2  
Soy isolate protein formula administration is 
often debated because although it does not contain 
cow’s milk protein, 10–14% children with CMPA 
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are also allergic to soy and SIF adverse reaction such 
as enterocolitis occurred in 30–64% CMPA 
children.5,6,7 This condition is a challenge for 
clinician and may be taken into consideration. Some 
researchers also debated about its conflicting 
evidence about the risks and benefits of phyto-
estrogens contained in SIF.8  
The consumption of SIF is a rational option 
when mature infants are not able to get breastfeeding 
and intolerance to cow’s milk is present. Another 
indication of SIF is galactosemia, hereditary lactase 
deficiency and conditions that require vegetarian 
diet and to reduce colic complaints. However, the 
benefits of SIF beyond allergies are yet widely 
known. Therefore, in this review, the Soy Infant 
Formula safety issues and its benefits beyond 
allergies are discussed. 
 
Soy infant formula usage in Indonesia 
 
The utilization rates of Soya Infant Formula (SIF) 
have been repeatedly found to be higher than 
expected compared to the reported incidence of over 
mentioned indications for SIF use. It was reported 
that SIF was used nearly 20 % in Canada (year 
2005)9 and 25% in the USA (year 2008).6 A recent 
evaluation of the consumption of different types of 
feeding among a nationally representative sample of 
1,864 infants aged 0–12 months in the USA reported 
that among 81% of infants who were fed formula or 
regular milk and 12% consumed SIF.10 However, 
SIF is only used for management of Cow’s Milk 
Protein Allergy in Indonesia.2 This consensus is 
based on the AAP6 and the ESPGHAN4 which stated 
few indications for the use of SIF in infant. Several 
studies have shown that presently available SIF can 
allow for the normal growth and development of 
full-term infants. Moreover, full-term infants, 
galactosemia, and hereditary lactase deficiency are 
the only clinical conditions for which SIF are 
considered the best solution for feeding infants. 
Finally, they can be used when a vegan diet is 
preferred. Other clinical conditions that were 
initially considered possible indications for SIF use 
are presently preferentially treated with different 
nutritional approaches.11 It is also the consideration 
for the use of SIF in Indonesia.2 
According to the Indonesian Pediatrics 
Association (IDAI) Guidelines, the management of 
cow’s milk protein allergy (CMPA) consists of 
diagnosis and therapy in children with CMPA. 
Diagnosis can be performed in children by dietary 
elimination of cow’s milk protein, standardized oral 
challenge test, IgE specific test, skin test and patch 
test. Even though the gold standard for diagnosing 
CMPA is through a standardized oral test, many 
clinicians still diagnose CMPA based on symptoms. 
The therapy itself lies within the algorithm of 
avoiding the allergen which is cow’s milk protein. 
For breastfed infant, it is recommended for the 
mother to avoid the consumption of all cow’s milk 
protein and its derivatives. In IDAI guidelines, the 
therapy for CMPA is extensively hydrolyzed protein 
formula’s (eHF) although this formula is more 
expensive and less palatable than SIF since some 
cases are also suffer from soy protein allergy. It is 
stated in the IDAI Guidelines, however, if eHF is not 
available or too expensive for patients, soy infant 
formula (SIF) may be used but patients need to be 
educated with SIF adverse effects.2 
The World Health Organization (WHO) also 
mentioned soy infant formula in CODEX STAN 72-
1981 of Standard for Infant Formula and Formulas 
for Special Medical Purposes Intended for Infants. 
The minimum value of protein for soy infant 
formula based on soy protein isolate is 2.25 g/100 
kcal (0.5 g/100 kJ) based on CODEX. The 
Indonesian National Food and Drug Agency (Badan 
Pengawas Obat dan Makanan/BPOM) regulates soy 
infant formula and its minimum value of protein is 
in line with CODEX, which is 2.25 g/100 kcal and 
maximum of 3 g/100 kcal. This concludes that soy 
infant formula has met the standardized minimum 
for nutrients for infants and is regulated by BPOM 
though the intended use of SIF is not mentioned in 
the regulation.12,13. 
 
Benefits and challenges of soy infant formula 
 
The efficacy of SIF for CMPA management is often 
debated because although it does not contain cow’s 
milk protein, some children with CMPA are also 
allergic to soy. Some SIF adverse effects of SIF such 
as enterocolitis are also a consideration. Despite the 
low prevalence of soy allergy there is still a 
possibility of anaphylaxis risk in SIF.5 The AAP, the 
EPSGHAN and IDAI recommended SIF as a 
rational choice and can be justified in CMPA 
 World.Nutr.Journal | 26  
children.2,4,6 For breastfed infants, eliminating of all 
cow’s milk protein and other protein sources such as 
soy is required. For formula-fed infants, current 
options include specific allergen avoidance and the 
use of eHF and AAF. Their efficacy for CMPA is 
approximately 90% compared to other management 
such as SIF. However, the availability and the taste 
of the formula might be an issue for compliance, that 
is why SIF is considered as an alternative.14 
Medical indication of SIF is actually limited 
to galactosemia and primary lactase deficiency 
which are very rare conditions. There is no 
indication to recommend the use of SIF in the 
prevention of CMPA, treatment of colic or as a 
supplement to breastfeeding. Incidence of allergy to 
soy or cow milk proteins has been reported to be 
comparable. In addition to the limited medical 
indications, there is also some economic, religious 
and philosophical reasons to advice soy although 
eHF has shown evidence to be more effective. SIF is 
substantially cheaper than eHF and it is safe and 
does not financially burden patients. Some eHFs are 
derived from pork pancreas so religious decision 
might affect patient decision. In this situation, SIF is 
a preferable option than other formulas, especially if 
the patient requests for vegan diet.15 
The safety of SIF, however, is another 
debate. Although reports have shown infants with 
SIF showed normal development and growth, some 
have concerns with potential adverse effect of 
phytochemicals in SIF such as phyto-estrogens. SIF 
showed no significant difference when compared to 
cow’s milk formula and breast milk in parameters 
such as body length, weight and head 
circumference.3,16 Despite SIF’s high level of 
aluminum content, it has been shown that it is not a 
safety issue since the value is within the limit 
allowed by WHO and BPOM.12,13 Disorder of sexual 
development, hypothyroidism with euthyroid 
conditions and disorder of immune function have 
not been proven.3,6 
SIF administration and its safety issues on 
sexual development and hormonal disorders are 
often questioned due to isoflavones content which 
have active metabolites in blood. Isoflavones are 
phyto-estrogens that hypothetically may cause 
disruption of sexual development and disorders of 
hormonal development in infants. Many studies in 
animals and mice showed that soy affected sexual 
development but it turned out that humans have a 
different metabolism of isoflavones in blood. 
Isoflavone metabolites are 20–150 times higher in 
mice than in human. The study concluded that the 
soy interference with sexual development and 
hormonal should not be drawn from animal studies.5 
The isoflavone content in soy isolate formula is not 
significant to cause unfavorable side effect.6 
The administration of SIF is safe and cost 
effective for CMPA children if the children cannot 
tolerate eHF. Many studies showed contradicting 
results in regards of its safety but all of these were 
not proven and inconclusive.3,5,6,15  
 
SIF beyond allergies 
 
Based on the description above, numerous studies 
have documented normal growth and development 
in term neonates fed with SIF. The average energy 
intake in infants receiving soy protein-based 
formulas is equivalent to those achieved with cow 
milk formula. Serum albumin concentration, as a 
marker of nutritional adequacy is normal in infants 
with SIF.6 Mineral content in SIF has been adapted 
and modern SIF using hydrolyzed phytate does not 
affect growth and bone mineralization compared to 
cow’s milk formula and does not induce risk of 
malnutrition.16 
On the other hand, SIF is not recommended 
for preterm infants. Serum phosphorus 
concentrations are lower, and alkaline phosphatase 
concentrations are higher in preterm infants fed with 
SIF than they are in preterm infants fed cow milk-
based formula. As anticipated from these 
observations, the degree of osteopenia is increased 
in infants with low birth weight receiving SIF. The 
cow milk protein-based formulas designed for 
preterm infants are clearly superior to soy protein-
based formula for preterm infants.6 The AAP also 
concluded that the aluminium in SIF is not a safety 
issue, except in preterm infants and infants with 
renal failure, because their daily of aluminium intake 
is lower than 1 mg per day thus SIF contains <0.5 
mg/kg/day aluminium in infants consuming SIF 200 
mL/kg/day.2,6,16 Opportunity of using SIF in the 
recovery of acute infantile diarrhea complicated by 
secondary or transient lactase deficiency has been 
addressed in many studies. The duration of diarrhea 
has been reported to be shorter in infants receiving 
 World.Nutr.Journal | 27  
SIF and the duration of liquid stools may also be 
reduced with additional soy polysaccharide fiber 
compared to human milk and cow-based formula. 
However, after rehydration, most infants can be 
managed successfully with continued breastfeeding 
or standard cow milk or SIF. Because primary or 
congenital lactase deficiency is rare, very few 
individuals would require a total restriction of 
lactose. Lactose intolerance is more likely to be dose 
dependent. Thus, the use of soy protein-based 
lactose-free formulas for this indication should be 
restricted.6,17 
The most common reason for using SIF by 
care providers is to relief of perceived formula 
intolerance (spitting, vomiting, and fussiness) or 
symptoms of colic since this can be a symptom of 
CMPA also.17 Effect of partially hydrolysed formula 
have not concluded in this particular area. 18 Colicky 
discomfort is often described by the parents during 
the first 3 months of age in 10–20% infants. Parents 
frequently seek relief by changing infant formula, 
although many factors can cause this behaviour. The 
benefit of SIF to calm colic is not significant, it 
might be attributed to sucrose and fiber content. 
Education and Communication to parents are key in 
addition to switching to SIF because colic-related 
behaviour will pass spontaneously between 4 and 6 
months of age.6 
 
Optimizing growth and development with SIF 
 
Isolated soy protein-based formulas currently on the 
market are all free of cow milk protein and lactose 
and provide 67 kcal/dL. All formulas are iron-
fortified and meet the vitamin, mineral, and 
electrolyte specifications addressed in the 2004 
guidelines from the AAP for feeding term infants 
and established by the US Food and Drug 
Administration. In Indonesia, all SIF are subject to 
the BPOM regulation13. The protein in SIF is a soy 
isolate supplemented with L-methionine, L-
carnitine, and taurine to provide a protein content of 
2.45 to 2.8 g per 100 kcal or 1.65 to 1.9 g/dL. The 
fat content of soy protein-based formulas is derived 
primarily from vegetable oils. The quantity of 
specific fats varies by manufacturer and is usually 
similar to those in the manufacturer's corresponding 
cow milk-based formula. The fat content ranges 
from 5.02 to 5.46 g per 100 kcal or 3.4 to 3.6 g/dL. 
The oils used include soy, palm, sunflower, olein, 
safflower, and coconut. Docosahexaenoic and 
arachidonic acids now are added routinely.2,6 
In formulas, carbohydrate sources are corn 
maltodextrin, corn syrup solids, and sucrose, with 
content ranging from 10.26 to 10.95 g per 100 kcal 
or 6.9 to 7.4 g/dL. Until 1980, mineral absorption 
from soy formulas was bad since as mentioned 
above SIF contains 1.5% phytate and 30% 
phosphorus is phytate bound. With the current 
formulations, bone mineralization, serum 
concentrations of calcium and phosphorus, and 
alkaline phosphatase concentrations in term infants 
through 12 months of age are equivalent to those 
observed in infants fed with cow milk-based 
formulas. Because soy phytates and fiber 
oligosaccharides also bind iron and zinc, all soy-
based formulas are fortified with iron and zinc.6,16  
Isoflavones are commonly found in legumes, 
with the highest amount found in soybeans. 
Concerns have been raised in relation to phyto-
estrogens/isoflavones include their potential 
negative effects on sexual development and 
reproduction, neurobehavioral development, 
immune function, and thyroid function. But as 
mentioned above, the studies are inconclusive and 
has not been proven.3,8 
High content of aluminium in soy-based 
formulas is debated since the first SIF was 
established. Although the aluminium content of 
human milk is 4 to 65 ng/mL, that of soy protein-
based formula is 600 to 1300 ng/mL. The toxicity of 
aluminium is traced to increased deposition in bone 
and in the central nervous system, particularly in the 
presence of reduced renal function in preterm infants 
and children with renal failure. Term infants with 
normal renal function do not seem to be at 
substantial risk of developing aluminium toxicity 
from soy protein-based formulas.2,3,6  
It is important for pediatricians to know that 
SIF is adapted to the nutritional needs of infants and 
SIF fed infants have a normal growth and 
development. The medical indications for soy are 
very limited, but the use of SIF is mostly for CMPA 
in Indonesia. Efforts should be made to increase 
breastfeeding rate and duration but SIF remains 
valid option for term born infants if breastfeeding is 
not possible and cow’s milk formula is not tolerated. 
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Conclusion 
 
The use of Soy Infant Formula (SIF) are widely 
known for the treatment and management of Cow’s 
Milk Protein Allergy (CMPA) but other than allergy, 
SIF has met nutritional needs for term born infants 
if breastfeeding is not possible and cow’s milk 
formula is not tolerated. The debate about the safety 
issues on SIF is ranging from sexual development 
disorder, hypothyroidism and low immune system 
and its correlation to SIF levels of aluminium, 
phytate and isoflavone. However, recent studies 
showed that all of these were not proven and 
inconclusive. Medical indications of using SIF are 
limited to CMPA, galactosemia and primary lactase 
deficiency, but there is room for SIF utilization 
beyond allergies.   
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